Correlation between APOBEC groups and selected clinical features
Head and Neck Squamous Cell Carcinoma (Primary solid tumor)
28 January 2016  |  analyses__2016_01_28
Maintainer Information
Citation Information
Maintained by Hailei Zhang (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2016): Correlation between APOBEC groups and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1Z31Z16
Overview
Introduction

This pipeline computes the correlation between APOBRC groups and selected clinical features.

Summary

Testing the association between APOBEC groups identified by 2 different apobec score and 14 clinical features across 511 patients, 6 significant findings detected with Q value < 0.25.

  • 3 subtypes identified in current cancer cohort by 'APOBEC MUTLOAD MINESTIMATE'. These subtypes correlate to 'YEARS_TO_BIRTH',  'PATHOLOGY_T_STAGE', and 'GENDER'.

  • 3 subtypes identified in current cancer cohort by 'APOBEC ENRICH'. These subtypes correlate to 'YEARS_TO_BIRTH',  'GENDER', and 'YEAR_OF_TOBACCO_SMOKING_ONSET'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between APOBEC groups by 2 different APOBEC scores and 14 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 6 significant findings detected.

Clinical
Features
Statistical
Tests
APOBEC
MUTLOAD
MINESTIMATE
APOBEC
ENRICH
Time to Death logrank test 0.267
(0.623)
0.245
(0.623)
YEARS TO BIRTH Kruskal-Wallis (anova) 0.000556
(0.0156)
0.0032
(0.0415)
PATHOLOGIC STAGE Fisher's exact test 0.315
(0.666)
0.48
(0.707)
PATHOLOGY T STAGE Fisher's exact test 0.0475
(0.222)
0.625
(0.828)
PATHOLOGY N STAGE Fisher's exact test 0.227
(0.623)
0.464
(0.707)
PATHOLOGY M STAGE Fisher's exact test 1
(1.00)
1
(1.00)
GENDER Fisher's exact test 0.00445
(0.0415)
0.044
(0.222)
RADIATION THERAPY Fisher's exact test 0.648
(0.828)
0.346
(0.666)
HISTOLOGICAL TYPE Fisher's exact test 0.783
(0.914)
0.899
(1.00)
NUMBER PACK YEARS SMOKED Kruskal-Wallis (anova) 0.106
(0.37)
0.214
(0.623)
YEAR OF TOBACCO SMOKING ONSET Kruskal-Wallis (anova) 0.357
(0.666)
0.0321
(0.222)
NUMBER OF LYMPH NODES Kruskal-Wallis (anova) 0.467
(0.707)
0.0884
(0.354)
RACE Fisher's exact test 0.462
(0.707)
0.68
(0.828)
ETHNICITY Fisher's exact test 0.963
(1.00)
0.665
(0.828)
APOBEC group #1: 'APOBEC MUTLOAD MINESTIMATE'

Table S1.  Description of APOBEC group #1: 'APOBEC MUTLOAD MINESTIMATE'

Cluster Labels 0 HIGH LOW
Number of samples 246 129 136
'APOBEC MUTLOAD MINESTIMATE' versus 'YEARS_TO_BIRTH'

P value = 0.000556 (Kruskal-Wallis (anova)), Q value = 0.016

Table S2.  Clustering Approach #1: 'APOBEC MUTLOAD MINESTIMATE' versus Clinical Feature #2: 'YEARS_TO_BIRTH'

nPatients Mean (Std.Dev)
ALL 510 61.0 (12.0)
0 245 58.8 (12.2)
HIGH 129 64.6 (11.3)
LOW 136 61.7 (11.2)

Figure S1.  Get High-res Image Clustering Approach #1: 'APOBEC MUTLOAD MINESTIMATE' versus Clinical Feature #2: 'YEARS_TO_BIRTH'

'APOBEC MUTLOAD MINESTIMATE' versus 'PATHOLOGY_T_STAGE'

P value = 0.0475 (Fisher's exact test), Q value = 0.22

Table S3.  Clustering Approach #1: 'APOBEC MUTLOAD MINESTIMATE' versus Clinical Feature #4: 'PATHOLOGY_T_STAGE'

nPatients T0+T1 T2 T3 T4
ALL 47 137 99 172
0 27 71 46 78
HIGH 8 27 19 56
LOW 12 39 34 38

Figure S2.  Get High-res Image Clustering Approach #1: 'APOBEC MUTLOAD MINESTIMATE' versus Clinical Feature #4: 'PATHOLOGY_T_STAGE'

'APOBEC MUTLOAD MINESTIMATE' versus 'GENDER'

P value = 0.00445 (Fisher's exact test), Q value = 0.042

Table S4.  Clustering Approach #1: 'APOBEC MUTLOAD MINESTIMATE' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 138 373
0 54 192
HIGH 49 80
LOW 35 101

Figure S3.  Get High-res Image Clustering Approach #1: 'APOBEC MUTLOAD MINESTIMATE' versus Clinical Feature #7: 'GENDER'

APOBEC group #2: 'APOBEC ENRICH'

Table S5.  Description of APOBEC group #2: 'APOBEC ENRICH'

Cluster Labels FC.HIGH.ENRICH FC.LOW.ENRICH FC.NO.ENRICH
Number of samples 224 41 246
'APOBEC ENRICH' versus 'YEARS_TO_BIRTH'

P value = 0.0032 (Kruskal-Wallis (anova)), Q value = 0.042

Table S6.  Clustering Approach #2: 'APOBEC ENRICH' versus Clinical Feature #2: 'YEARS_TO_BIRTH'

nPatients Mean (Std.Dev)
ALL 510 61.0 (12.0)
FC.HIGH.ENRICH 224 63.3 (11.2)
FC.LOW.ENRICH 41 62.2 (12.3)
FC.NO.ENRICH 245 58.8 (12.2)

Figure S4.  Get High-res Image Clustering Approach #2: 'APOBEC ENRICH' versus Clinical Feature #2: 'YEARS_TO_BIRTH'

'APOBEC ENRICH' versus 'GENDER'

P value = 0.044 (Fisher's exact test), Q value = 0.22

Table S7.  Clustering Approach #2: 'APOBEC ENRICH' versus Clinical Feature #7: 'GENDER'

nPatients FEMALE MALE
ALL 138 373
FC.HIGH.ENRICH 71 153
FC.LOW.ENRICH 13 28
FC.NO.ENRICH 54 192

Figure S5.  Get High-res Image Clustering Approach #2: 'APOBEC ENRICH' versus Clinical Feature #7: 'GENDER'

'APOBEC ENRICH' versus 'YEAR_OF_TOBACCO_SMOKING_ONSET'

P value = 0.0321 (Kruskal-Wallis (anova)), Q value = 0.22

Table S8.  Clustering Approach #2: 'APOBEC ENRICH' versus Clinical Feature #11: 'YEAR_OF_TOBACCO_SMOKING_ONSET'

nPatients Mean (Std.Dev)
ALL 276 1967.3 (12.8)
FC.HIGH.ENRICH 117 1967.2 (13.4)
FC.LOW.ENRICH 21 1960.5 (12.4)
FC.NO.ENRICH 138 1968.5 (12.1)

Figure S6.  Get High-res Image Clustering Approach #2: 'APOBEC ENRICH' versus Clinical Feature #11: 'YEAR_OF_TOBACCO_SMOKING_ONSET'

Methods & Data
Input
  • APOBEC groups file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/APOBEC_Pipelines/HNSC-TP/22536208/APOBEC_clinical_corr_input_22541982/APOBEC_for_clinical.correlaion.input.categorical.txt

  • Clinical data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/Append_Data/HNSC-TP/22506490/HNSC-TP.merged_data.txt

  • Number of patients = 511

  • Number of selected clinical features = 14

APOBEC classification

APOBEC classification based on APOBEC_MutLoad_MinEstimate : a. APOBEC non group -- samples with zero value, b. APOBEC high group -- samples above median value in non zero samples, c. APOBEC low group -- samples below median value in non zero samples.

APOBEC classification based on APOBEC_enrich : a. No Enrichmment group -- all samples with BH_Fisher_p-value_tCw > 0.05, b. Low enrichment group -- samples with BH_Fisher_p-value_tCw = < 0.05 and APOBEC_enrich=<2, c. High enrichment group -- samples with BH_Fisher_p-value_tCw =< 0.05 and APOBEC_enrich>2.

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Fisher's exact test

For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[3] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)